The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan

CONCLUSIONS: The intensification of intermittent TKI therapy is associated with a higher incidence of MR3.0 loss, but those patients who maintain the MR3.0 molecular response at the end of the study have been frequently considered eligible for TFR. The HRQoL generally improved during the de-escalation therapy in both randomization arms.PMID:38369436 | DOI:10.1016/j.clml.2024.01.008

Source: Clinical Lymphoma and Myeloma - February 18, 2024 Category: Cancer & Oncology Authors: Michele Malagola Alessandra Iurlo Cristina Bucelli Elisabetta Abruzzese Massimiliano Bonifacio Fabio Stagno Gianni Binotto Marienlla D'Adda Monia Lunghi Monica Crugnola Maria Luisa Ferrari Francesca Lunghi Fausto Castagnetti Gianantonio Rosti Roberto Mass Source Type: research